People: Insmed Inc (INSM.OQ)
INSM.OQ on NASDAQ Stock Exchange Capital Market
10.04USD
4:00pm EDT
10.04USD
4:00pm EDT
Price Change (% chg)
$0.32 (+3.29%)
$0.32 (+3.29%)
Prev Close
$9.72
$9.72
Open
$9.91
$9.91
Day's High
$10.15
$10.15
Day's Low
$9.70
$9.70
Volume
309,568
309,568
Avg. Vol
115,828
115,828
52-wk High
$14.30
$14.30
52-wk Low
$2.86
$2.86
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Donald Hayden |
56 | 2012 | Non-Executive Chairman of the Board |
William Lewis |
43 | 2012 | President, Chief Executive Officer, Director |
Andrew Drechsler |
40 | 2012 | Chief Financial Officer, Principal Financial and Accounting Officer |
Renu Gupta |
56 | 2010 | Executive Vice President - Development, Chief Medical Officer |
Matthew Pauls |
2013 | Chief Commercial Officer | |
Randall Whitcomb |
57 | 2012 | Lead Independent Director |
Al Altomari |
2012 | Director | |
Steinar Engelsen |
63 | 1999 | Independent Director |
Richard Kollender |
42 | 2011 | Independent Director |
Melvin Sharoky |
61 | 2010 | Independent Director |
Brian Ritchie |
IR Contact |
Biographies
| Name | Description |
|---|---|
Donald Hayden |
Mr. Donald J. Hayden, Jr., is the Non-Executive Chairman of the Board of Insmed Inc. In 2010, Mr. Hayden became Chairman of Insmed following the merger with Transave. He had previously served as Executive Chairman of Transave since April 2006. Mr. Hayden also currently serves as Lead Independent Director of Amicus Therapeutics and Director of Otsuka Pharmaceuticals. He also serves in Board roles for several privately-held companies, including Executive Chairman of Azelon Pharmaceuticals, Chairman of Vitae Pharmaceuticals and Satori Pharmaceuticals, and Director of Nora Therapeutics. Mr. Hayden is also a senior advisor to Prospect Venture Partners, a venture capital firm. From 1981 to 2006, he had a 25 year career with Bristol-Myers Squibb Company, where he served in key executive roles such as President of Global Pharmaceuticals; Executive Vice President and President, Americas; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President of Worldwide Franchise Management and Business Development. Mr. Hayden holds a B.A. from Harvard University and an M.B.A. from Indiana University. |
William Lewis |
Mr. William H. Lewis has been appointed as President, Chief Executive Officer, Director of Insmed Inc., effective September 10, 2012. He has been engaged by the Company as an advisor since June 2012. Mr. Lewis was a co-founder of Aegerion Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company that focuses on the development and commercialization of novel, life-altering therapeutics to treat debilitating and often fatal rare diseases, and served as its President and Chief Financial Officer from March 2005 to June 2011. Prior to that, Mr. Lewis served in a variety of investment banking positions with Wells Fargo Securities (2002 to 2004), Robertson Stephens (2000 to 2002) and J.P. Morgan & Co. (1995 to 2000). |
Andrew Drechsler |
Mr. Andrew T. Drechsler has been appointed as the Chief Financial Officer, Principal Financial and Accounting Officer of Insmed Inc., effective November 8, 2012. Mr. Drechsler offers 15 years of financial and operational leadership experience in both public and private life sciences companies. He joins Insmed from VaxInnate Corporation, a privately held clinical-stage biotechnology company developing vaccines for infectious diseases, where he was Chief Financial Officer. Previously, Mr. Drechsler was Chief Financial Officer of publicly-traded Valera Pharmaceuticals. He was also responsible for all Securities and Exchange Commission reporting at Valera. Mr. Drechsler's public company and financial reporting duties have also included serving as Controller for a variety of companies, including Abbott Laboratories' Point of Care Division, which was publicly-traded as i-Stat Corporation prior to being acquired by Abbott, and Biomatrix, Inc., which was publicly-traded prior to being acquired by Genzyme. He graduated Magna Cum Laude from Villanova University with a B.S. in Accounting and received his certified public accountant license in New Jersey. |
Renu Gupta |
Dr. Renu Gupta, M.D., has been appointed as Executive Vice President - Development, Chief Medical Officer of Insmed Inc., effective December 2010. Dr. Gupta has served as the Executive Vice President Development and Chief Medical Officer of Transave since September 2006. From May 2003 to August 2006, she held the position of Senior Vice President Development at Antigenics, Inc. Prior to that, she served at Novartis as Vice President and Head of U.S. Clinical Research and Development and Global Head of Cardiovascular, Metabolics, Endocrine and Gastroenterology Research. Dr. Gupta also spent almost 10 years at Bristol-Myers Squibb, where she was responsible for clinical research, business development and global development and marketing strategy for infectious diseases and immunology. Dr. Gupta received her bachelor and medical degrees from the University of Zambia and completed her medical and post-doctoral training at Albert Einstein Medical Center, the Wistar Institute of Anatomy and Biology, Children’s Hospital of Philadelphia, and the University of Pennsylvania, where she was Adjunct Assistant Professor until 1997. Dr. Gupta has more than 25 years of development, regulatory and senior management experience with the biopharma industry. Her work has been published in peer-reviewed journals and she has been active in numerous relevant academic and professional societies. Dr. Gupta is a founding member of the Industrial Management Board at the Harvard Medical School, served as Chair of the Medical Advisory Council for Antigenics, past member of the Scientific Advisory Board at Cerimon Pharmaceuticals, and the Institute of Medicine Forum on Emerging Infections, and is a board member of Aim at Melanoma, formerly Charlie Guild Melanoma Foundation. |
Matthew Pauls |
Mr. Matthew Pauls has been appointed as Chief Commercial Officer of Insmed Incorporated. Prior to joining Insmed, Mr. Pauls was with Shire Pharmaceuticals, most recently as Senior Vice President, Head of Global Commercial Operations, Shire Regenerative Medicine. In this role, Mr. Pauls led the global commercial function of a business unit with a staff of approximately 300 including a 200-person U.S. sales team with approximately $160 million in sales. Previously he was Vice President, Product General Manager, Shire Specialty Pharmaceuticals Behavioral Health Business Unit, where he had P&L responsibility for Vyvanse(R) in the U.S. and Intuniv(R) globally. Vyvanse(R) is Shire's top-selling drug in the U.S. and Intuniv(R) is a key product in Shire's global attention deficit hyperactivity disorder (ADHD) franchise. Mr. Pauls holds BS and MBA degrees from Central Michigan University and a JD from Michigan State University College of Law. |
Randall Whitcomb |
Dr. Randall W. Whitcomb, M.D., has been appointed as Lead Independent Director of Insmed Inc., effective May 16, 2012. Dr. Whitcomb has been a member of Insmed's Board since November 2001. Since mid-2007, Dr. Whitcomb has served as a Senior Advisor to the Biopharma investment team of Frazier Healthcare. Dr. Whitcomb was a Founder of Quatrx Pharmaceuticals, Inc., a privately-held, drug development company focusing on discovery, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular areas, where he served as Chief Medical Officer from 2001 to 2006. From 1992 through 2000, he held various management positions with Parke-Davis Pharmaceutical Research, Inc., a division of Warner Lambert Company, serving as Vice President of Drug Development with particular responsibility for the development and approval of products for women's health care, metabolic diseases and diabetes. After the merger of Warner Lambert into Pfizer, Inc., Dr. Whitcomb was Vice-President Global Project Management for Pfizer Global Research and Development. From 1987 through 1992 he was on the faculty of Massachusetts General Hospital and Harvard Medical School. |
Al Altomari |
Mr. Al Altomari has been appointed as Director of Insmed Inc., effective August 02, 2012. Since October 2010, Mr. Altomari has served as President and Chief Executive Officer of Agile Therapeutics, a privately-held pharmaceutical company specializing in women’s healthcare products, where he is also a member of the company’s Board of Directors. Mr. Altomari is Agile through the final stages of development and commercialization of contraceptive products using the company’s proprietary transdermal technology. Before joining Agile, Mr. Altomari held multiple senior management positions over a five year period at Barrier Therapeutics. During his tenure with Barrier, he put in place the company’s commercial infrastructure and all sales and marketing functions for Barrier’s product portfolio, and oversaw management of all worldwide business development initiatives. In 2008, in his role as Chief Executive Officer, and as a member of the company’s Board of Directors, Mr. Altomari completed the sale of the company to GlaxoSmithKline/Stiefel Laboratories. Prior to joining Barrier, Mr. Altomari held numerous executive roles in general management, commercial operations, business development, product launch preparation, and finance with Johnson & Johnson from 1982 to 2003. He completed his tenure with Johnson & Johnson as General Manager of Ortho Neutrogena. Mr. Altomari currently serves as a member of the Boards of Directors of DUSA Pharmaceuticals and Nitric Bio Therapeutics. In July 2007, he was recognized by PharmaVoice Magazine as one of the Top 100 Most Inspirational and Influential leaders in the Life Sciences Industry. He received a Masters in Business Administration from Rider University and his Bachelor of Science from Drexel University. Mr. Altomari also serves on the advisory board for Le Bow College, Drexel University’s business school. |
Steinar Engelsen |
Dr. Steinar J. Engelsen, M.D.,C.E.F.A. has been Independent Director of Insmed Inc. He has been a member of the company's Board since inception in November 1999 and was a director of Insmed Pharmaceuticals, the company's predecessor entity, from 1998 to 2000. Since November 1996, Dr. Engelsen has been a partner of Teknoinvest AS, a venture capital firm based in Norway. In addition, from January to November 2000, Dr. Engelsen was acting CEO of Centaur Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 until October 1996, Dr. Engelsen held various management positions within Hafslund Nycomed AS, a pharmaceutical company based in Europe, and its affiliated companies. He was responsible for therapeutic research and development, most recently serving as Senior Vice President, Research and Development of Nycomed Pharma AS from January 1994 until October 1996. Dr. Engelsen received his M.Sc. in nuclear chemistry and his M.D. from the University of Oslo, and is a Certified European Financial Analyst (C.E.F.A.). |
Richard Kollender |
Mr. Richard S. Kollender has been appionted as Independent Director of Insmed Inc., with effect from January 2011. He has served as a partner at Quaker Partners Management, L.P. (formerly Quaker BioVentures), a venture capital firm with a focus on the healthcare industry, since 2005 and was a principal with Quaker Partners Management, L.P. from 2003-2005. Previously, Mr. Kollender served in a variety of sales, marketing and worldwide business development positions at GlaxoSmithKline, as an Investment Manager at SR One and as a Certified Public Accountant with KPMG LLP, with a emphasis on the healthcare and emerging businesses sectors. Mr. Kollender holds a B.A. from Franklin and Marshall College in Accounting and Business Administration, an MBA from the University of Chicago and a certificate from the graduate program in Health Administration and Policy from the University of Chicago. From December 2007 to June 2011, he served on the Board of Directors and as the Chairman of the audit committee of NuPathe Inc. (NASDAQ: PATH) and currently serves on the boards of directors of several privately held companies, including Precision Therapeutics, Inc., Rapid Micro Biosystems, Inc., and Transport Pharmaceuticals, Inc. He also serves as an observer of the Board of Directors of Celator Pharmaceuticals, Inc. Mr. Kollender previously served on the Board of Directors of Transave prior to the merger with Insmed. |
Melvin Sharoky |
Dr. Melvin Sharoky, M.D. is Independent Director of Insmed Inc. He has been a member of the company's Board since May 2001 and served as the company's Chairman of the Board from June 2009 to December 2010. From January 2002 to March 2007, he was President and Chief Executive Officer (CEO) of Somerset Pharmaceuticals, Inc., a research and development pharmaceutical company which markets Eldepryl® for the treatment of patients with late stage Parkinson’s disease and developed EMSAM®, which was licensed to Bristol-Myers Squibb, for the treatment of patients with a depressive disorder. Dr. Sharoky continued as a consultant to Somerset until December 2007. He previously served as President of Somerset Pharmaceuticals from July 1995 to June 2001. From June 2001 to January 2002, Dr. Sharoky was retired. From July 1995 through January 1998, Dr. Sharoky was President of Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, and from February 1993 to January 1998 he was also President and CEO of its wholly-owned subsidiary, Circa Pharmaceuticals, Inc., which develops, manufactures and markets solid dosage generic pharmaceutical products to wholesale distributors. Dr. Sharoky joined Circa Pharmaceuticals in July 1988 as Medical Director, served as Senior Vice President and Director of Research and Development from April 1991 to August 1992, and as Executive Vice President and Director of Research and Development from August 1992 to January 1993. From February 1986 to June 1988, he was Vice President and Chief Medical Officer of Pharmakinetics Laboratories, Inc. He is currently a member of the Board of Directors of Par Pharmaceuticals (NYSE:PRX). Dr. Sharoky received a B.A. in biology from the University of Maryland in Baltimore County and an M.D. from the University of Maryland School of Medicine. |
Brian Ritchie |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Donald Hayden |
-- |
William Lewis |
-- |
Andrew Drechsler |
-- |
Renu Gupta |
1,207,710 |
Matthew Pauls |
-- |
Randall Whitcomb |
-- |
Al Altomari |
-- |
Steinar Engelsen |
-- |
Richard Kollender |
-- |
Melvin Sharoky |
-- |
Brian Ritchie |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Donald Hayden |
0 | 0 |
William Lewis |
0 | 0 |
Andrew Drechsler |
0 | 0 |
Renu Gupta |
0 | 0 |
Matthew Pauls |
0 | 0 |
Randall Whitcomb |
0 | 0 |
Al Altomari |
0 | 0 |
Steinar Engelsen |
0 | 0 |
Richard Kollender |
0 | 0 |
Melvin Sharoky |
0 | 0 |
Brian Ritchie |
0 | 0 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
